The demand for weight loss drugs in the U.S. is on the rise, despite limited insurance coverage and high costs, according to a recent survey conducted by Evercore ISI on GLP-1 medications. Popular drugs like Wegovy, Ozempic, Zepbound, and Mounjaro were included in the survey.
The findings of the survey revealed that patients’ willingness to pay for GLP-1 treatments varies significantly based on their annual income. Patients with higher incomes are more willing to pay out of pocket for weight loss drugs, with 60% of those earning over $250,000 stating they would pay more than $300 per month.
In contrast, only 4% of those earning less than $75,000 said they would pay over $300 per month, with 64% indicating they would only be willing to pay $50 or less out of pocket. This discrepancy raises concerns about equity in access to weight loss drugs, as insurance coverage remains sparse and high prices may serve as a barrier for those with lower incomes.
The survey highlights the financial challenges faced by individuals with lower incomes who are seeking weight loss treatment. As the demand for weight loss drugs continues to grow, it is crucial to address these barriers and ensure that all individuals have access to affordable and effective treatments. Stay tuned to Swerd Media for more updates on this important issue.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”